Trends in Medication Management. Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management
|
|
- Amy Short
- 5 years ago
- Views:
Transcription
1 Trends in Medication Management Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management
2 Agenda Drug Claims Trends Legislative / Public Plan Initiatives Biosimilars Pipeline Focus on Oncology 2
3 Drug Claims Trends
4 Top 10 Drug Classes by Adjudicated Amount Therapeutic Class Rank (by Adjudicated Amount) % Percent of Total Adjudicated Amount Immunomodulators (e.g. RA) % 11.0% Diabetes % 8.3% Depression % 6.0% Asthma % 5.5% Skin Disorders % 4.2% Blood Pressure % 4.5% Antibiotics/Anti-Infectives % 4.4% Ulcers % 4.1% Multiple Sclerosis % 3.1% ADD/Narcolepsy % 2.9% Share Of Total Adjudicated Amount 54.7% 54.0% 4
5 Top 15 Brand Single-Source by Adjudicated Amount Trade Name Disease Name % Percent of Adjudicated Amount Avg. Eligible Cost/ Claimant % Percent Change in Claimants over 2015 Remicade Rheumatoid Arthritis ,590 4 Humira Rheumatoid Arthritis , Enbrel Rheumatoid Arthritis ,020-3 Stelara Skin Disorders , Advair Asthma Symbicort Asthma Concerta ADD/Narcolepsy Coversyl Blood Pressure Harvoni Hepatitis , Vyvanse ADD/Narcolepsy Cymbalta Depression Xolair Asthma , Victoza Diabetes 1.1 1,875 4 Janumet Diabetes Abilify Mental Disorders Total 30.4 $1,
6 Legislative / Public Plan Initiatives
7 Multiple impactful trends Federal Bill S-201 on genetic discrimination. Medical marijuana coverage. A report from the Conference Board of Canada estimates savings of $1B for switching three categories of medication from prescription to over-the-counter (OTC). OHIP+ : New pharmacare program in Ontario providing 100 % coverage for all residents aged < 25 years old. Quebec Bill 81 allows for tendering processes for Basic Drug Plan listing of generic drugs. Similar to other provinces, Quebec will implement a blood glucose test strip limitation to its public plan (RAMQ). Operational changes to the Trillium Drug Program in Ontario allow for electronic claims transmission. Access to Hepatitis C drugs is expanding in BC and more drugs are funded in Ontario. 7
8 Quebec Bill 92 - Overview Wide scope: Investigation powers of the RAMQ, commercial practices related to prescription drugs, voluntary termination of pregnancy Transparency of pharmacy invoices Financial support from pharmaceutical manufacturers Private payer s preferred provider networks Delisting of drugs from the RAMQ List of Medications 8
9 September 15th 2017: pharmacy invoices will be more transparent For drugs listed on the RAMQ List of Medications only Drug Cost $23.71 Wholesaler s Mark-Up Dispensing Fee (including retail markup or other fees) $1.54 $8.96 9
10 Impacts of Bill 92 Plan members will be better equiped to seek pharmacies offering the best prices. Pharmacists may potentially lower their prices or limit their price increases. Invoices may become challenging to understand for plan members. Plan design impact will be highly dependent on claim submission by pharmacies. 10
11 No limits on limits! Proton Pump Inhibitors Quebec implemented new PPI limitations on May 3rd, day Supply allowed within a 365-day period Larger Supply allowed through exception codes Projected savings for the Quebec Public Plan (RAMQ): 14M$ on a 167M$ PPI expenditure Source: Usage optimal à long terme des inhibiteurs de la pompe à protons. May
12 Biosimilars Update
13 Five biosimilar drugs are currently available Biosimilar Reference Product Biosimilar Indications Product Availability OMNITROPE (somatropin) GENOTROPIN Growth Hormone Deficiency 2009 INFLECTRA (infliximab) REMICADE Rheumatoid Arthritis / Ankylosing Spondylitis Plaque Psoriasis / Psoriatic Arthritis Crohn Disease / Ulcerative Colitis * Not indicated for pediatric patients September 2014 BASAGLAR (glargine insulin) GRASTOFIL (filgrastim) LANTUS Type 1 / Type 2 Diabetes December 2015 NEUPOGEN Neutropenia March 2016 BRENZYS (etanercept) ENBREL Rheumatoid Arthritis / Ankylosing Spondylitis * Not indicated for Plaque Psoriasis / Psoriatic Arthritis ** Not indicated for pediatric patients September 2016 ERELZI (etanercept) ENBREL Rheumatoid Arthritis / Ankylosing Spondylitis Juvenile Idiopathic Arthritis (4-17 y.o.) * Not indicated for Plaque Psoriasis / Psoriatic Arthritis TBC 13
14 The impact of biosimilars remains limited in private drug plans According to the 2016 TELUS Health Book of Business, utilization and costs of three recently approved biosimilars represent : < 1 % of claimants for the chemical entity < 0,5 % of costs associated to the chemical entity INFLECTRA (infliximab) BASAGLAR (glargine insulin) GRASTOFIL (filgrastim) BRENZYS & ERELZI (etanercept) $ 0.37 % 0.25 % 0.41 % Claimants 0.84 % 0.61 % 0.99 % Too soon to tell New Claimants Only 3.75 % 2.5 % 1.2 % Too soon to tell TELUS Health Book of Business. Canada
15 Biosimilar Pipeline Update Reference Drug Indications Manufacturers (Biosimilar Name) Anticipated Approval Date AVASTIN (bevacizumab) Cancer (many indications) Pfizer (PF ) Health Canada is currently reviewing a submission for bevacizumab NEULASTA (pegfilgrastim) Neutropenia Mylan Health Canada is currently reviewing a submission for pegfilgrastim HUMIRA (adalimumab) Rhumatoid Arthritis / Inflammatory Diseases Amgen (ABP501) Also: Sandoz, BI et Merck Q1-Q LUCENTIS (ranibizumab) Macular Degeneration Pfenex (PF582) Also: Hospira, Novartis et Valeant Potentially 2018 HERCEPTIN (trastuzumab) Breast Cancer Celltrion (CT-P6) Also: Pfizer Potentially 2018 RITUXAN (rituximab) Lymphoma (RA phase 3) Sandoz (GP2013) Potentially late 2018 TELUS Health. Drug Pipeline Tracker. March
16 Pipeline Update
17 Pipeline Update Drug Indication Potential Impact Cost OCALIVA (obeticholic acid) Intercept A farnesoid X receptor agonist indicated for primary biliary cholangitis (approx. 10,000 patients in Canada): Approved by the FDA in May Health Canada approval is expected in the next few months. Off-label use potential for non alcoholic steatohepatitis (NASH) a much more prevalent condition (2 to 5 % of the general population). Cost expected to be $75,000 or more per year CGRP Inhibitors Many manufacturers Monoclonal antibodies (biologic drugs) targeting CGRP indicated for the prevention of chronic and episodic migraines. Global forecasts seem to indicate that approval will not be earlier than Highly anticipated new drug class targeting a highly prevalent medical condition (approx. 8% of Canadians). Expected cost between $9,000 to $20,000. EUCRISA (Crisaborole) Anacor / Pfizer Indicated for atopic dermatitis and potentially psoriasis Approved by the FDA for mild to moderate atopic dermatitis in December This is considerably more expensive that other therapies for atopic dermatitis such as topical steroids or immunomodulators. U.S. pricing has been set at $580 for a 60-gram tube TELUS. Health. Drug Pipeline Tracker. March
18 Thank You
Trends in Medication Management
Trends in Medication Management Cory Cowan, Pharm.D. Director Professional Services, TELUS Health Content Outline I. Therapy class review 2017 II. Legislative updates III. Biosimilars IV. Drug pipeline
More informationBiosimilars Market Update
Biosimilars Market Update Panel: Matthew Brougham Consultant Economist, Brougham Consulting Inc Mark Jackson Consultant Pharmacist, TELUS Health Dr. Ed Keystone Professor of Medicine, University of Toronto
More informationPerspectives Spring The Drug Pipeline: What s in it and why it matters.
Perspectives Spring 2017 The Drug Pipeline: What s in it and why it matters. 2 The Drug Pipeline: What s in it and why it matters. Mark Jackson, BScPhm, BComm, RPh Consultant Pharmacist, TELUS Health Introduction
More informationUBCM Conference. Joanne Jung, BScPharm Director, Pharmacy Services Mar 10, 2016
UBCM Conference Joanne Jung, BScPharm Director, Pharmacy Services Mar 10, 2016 Agenda Drug Landscape Private drug plan trends Cost drivers Specialty Drugs Drug Trends Top Therapeutic Classes Drug Plan
More informationRegulation of Biosimilars in Canada
Regulation of Biosimilars in Canada Session 2: Global Regulatory Trends of Biosimilars GBC 2018 June 28, 2018 Stephanie Hardy Office of Policy and International Collaboration Biologics and Genetic Therapies
More informationAN UPDATE ON SEBS SUMMER SEBs in the pipeline. Let s review... What s Inflectra?
SUMMER 2016 AN UPDATE ON SEBS Since we first covered subsequent-entry biologic drugs (SEBs), or biosimilars, in our fall 2014 issue of Follow the Script, this hot topic has gotten even hotter. Back then
More informationAn update on development strategies of recently approved biosimilars in Europe. Johanna Mielke
An update on development strategies of recently approved biosimilars in Europe Johanna Mielke Acknowledgement & disclaimer This project was supported by the Swiss State Secretariat for Education, Research
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More information: Regulation of biosimilars and success factors for uptake in clinical practice. Steinar Madsen, MD, FACP(Hon) Medical director
2018-02-08: Regulation of biosimilars and success factors for uptake in clinical practice Steinar Madsen, MD, FACP(Hon) Medical director steinar.madsen@legemiddelverket.no Drug costs in Norway Billion
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationBiosimilars 101: How similar are they?
Biosimilars 101: How similar are they? Matthew Marston, Pharm.D., BCPS, BCOP Senior Manager of Clinical Pharmacy Services Miller Drug, LLC Outline Describe the approval and manufacturing process of biologics
More informationThe New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products
The New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products Table of Contents Executive Director s Note Innovation & Access Biosimilars 101 Safety & Sameness How
More informationUnderstanding The World Of Specialty. And Why We Should Care?
Understanding The World Of Specialty Drugs And Why We Should Care? What Are Specialty Drugs? Specialty Drugs are drugs used for the treatment of complex conditions and they often require special storage,
More informationTABLE OF CONTENTS 1. INTRODUCTION 1.1 STUDY DELIVERABLES 1.2 MARKET DEFINITION 1.3 STUDY ASSUMPTIONS 2. RESEARCH METHODOLOGY 2.
TABLE OF CONTENTS 1. INTRODUCTION 1.1 STUDY DELIVERABLES 1.2 MARKET DEFINITION 1.3 STUDY ASSUMPTIONS 2. RESEARCH METHODOLOGY 2.1 INTRODUCTION 2.2 METHOD OF ANALYSIS 2.3 STUDY PHASES 2.4 SECONDARY RESEARCH
More informationPerspectives Spring The Drug Pipeline: What s in it and why it matters.
Perspectives Spring 2016 The Drug Pipeline: What s in it and why it matters. 2 The Drug Pipeline: What s in it and why it matters. Author: Mark Jackson, BScPhm, BComm, RPh Consultant Pharmacist, TELUS
More informationAre Biosimilars the Panacea for High Cost Specialty Drugs?
Are Biosimilars the Panacea for High Cost Specialty Drugs? Mid-sized Retirement and Healthcare Plan Management San Francisco, CA March 27, 2018 2018. Innovative Rx Strategies, LLC. All rights reserved.
More informationPharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Dr. Robinson declares no conflicts of interest, real or apparent, and
More informationPharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Pharmacist Objectives Dr. Robinson declares no conflicts of interest,
More informationWhat Is a Biosimilar?
Learning Objectives Compare and contrast biosimilars to their reference product and generic therapies in terms of structure, manufacturing, regulatory pathway, and clinical properties Evaluate evolving
More informationBiosimilar medicines: practical EU experience and perspectives. 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe
Biosimilar medicines: practical EU experience and perspectives 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe Medicines For Europe VISION Medicines for Europe Vision 2020 Our
More informationFormulary Considerations for Biosimilars in healthcare systems
Formulary Considerations for Biosimilars in healthcare systems Ahmed Aljedai, Pharm.D., M.B.A, BCPS, FCCP, FAST Assistant Deputy Minister for Therapeutic Affair, MOH,KSA Disclosure Information Formulary
More information29/04/2016. Biosimilars An NHS perspective. Aim. Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016
Biosimilars An NHS perspective Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016 Aim The changing medicines landscape driving patient access to medicines the Biosimilar
More informationNaming, tracing, switching and other safety issues after 10 years learning
Naming, tracing, switching and other safety issues after 10 years learning Prof. Dr. Irene Krämer, Department of Pharmacy Johannes Gutenberg-University Medical Center, Mainz (Germany) Disclosures Speaker
More informationSan Francisco Health Service System
San Francisco Health Service System Pharmacy Trends Board Forum: November 10, 2016 Prepared by: Aon s Pharmacy Point of View We Believe Getting patients to the RIGHT drug at the RIGHT channel for the RIGHT
More informationcontinuing education for pharmacists
continuing education for pharmacists Biologics and Biosimilars Volume XXXV, No. 8 Mona T. Thompson, R.Ph., PharmD, BCPS Dr. Mona Thompson has no relevant financial relationships to disclose. Goal. The
More informationImplementation of Biosimilars: The Good, the Bad, the Ugly September 13, Learning Objectives. Audience Response 9/3/2018
Implementation of Biosimilars: The Good, the Bad, the Ugly September 13, 2018 Monica Macik, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Hematology/Oncology Eskenazi Health Indianapolis, IN Karen Smethers,
More informationLondon Medicines Evaluation Network Review
London Medicines Evaluation Network Review Answers to commonly asked questions about biosimilar versions of infliximab February 2015 (revised April 2015) Authored by Nicola Hooker (Nicola.Hooker@gstt.nhs.uk)
More informationPharmacovigilance in Oncology. Luis H. Camacho, MD, MPH Houston, USA
Pharmacovigilance in Oncology Luis H. Camacho, MD, MPH Houston, USA 5th European Biosimilar Congress - Valencia June 27-29, 2016 Disclosure Director, Center for Oncology and Blood Disorders. Secretary,
More informationBiosimilar Development Clinical Investigator Considerations
Biosimilar Development Clinical Investigator Considerations June 2011 www.ppdi.com Biosimilar products are not new in the pharmaceutical industry. However, the pending expiration of numerous therapeutic
More informationHow are biosimilars assessed and approved?
How are biosimilars assessed and approved? Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific Advice
More informationGlobal Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity
Global Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual BioProcess International Europe 2012 Apr 18-19 Prague, Czech Republic BioProcess Technology
More informationWhat next? Manufacture the biosimilar product
What next? Manufacture the biosimilar product Design manufacturing process to match QTPP Full quality dossier required. Use state of the art technologies In accordance with relevant ICH and CHMP guidelines
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationSpecialty Pharmacy 101
Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current
More informationFuture Trends in Biopharmaceutical Operations and Facilities
Presentation ISPE-Workshop on Single-Use Technologies in Biomanufacturing Processes 26-27 th May 2011, Marseilles, France Future Trends in Biopharmaceutical Operations and Facilities Johannes R. Roebers,
More informationThis presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America
This presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America The development of this presentation was supported in 2016 by a sponsorship
More information2016 OptumRx Trend Insights
2016 OptumRx Trend Insights TREND SUMMARY Overall trend summary This report offers our perspective of the forces driving trend and spending for 2015 vs. 2016. We define trend as growth in year-over-year
More informationCurrent scenario of biosimilar
2018; 7(7): 188-193 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(7): 188-193 2018 TPI www.thepharmajournal.com Received: 16-05-2018 Accepted: 20-06-2018 Pooja Paul Department of
More informationSpecialty Drugs: Trends, Challenges and Solutions. Life s brighter under the sun. November2015
November2015 Specialty Drugs: Trends, Challenges and Solutions Join The Conversation, brought to you by Sun Life Financial Group Benefits. Life s brighter under the sun Foreword As someone tasked with
More informationBiologicals & biosimilars; addressing the needs of patients and payers. The Role of Functioning Competitive Markets
Biologicals & biosimilars; addressing the needs of patients and payers The Role of Functioning Competitive Markets Agenda Why do patients and payers need biosimilars? How can we increase the uptake of
More informationRISING COSTS FOR PATENTED DRUGS DRIVE GROWTH OF PHARMACEUTICAL SPENDING IN THE U.S.
RISING COSTS FOR PATENTED DRUGS DRIVE GROWTH OF PHARMACEUTICAL IN THE U.S. Rising Costs for Patented Drugs Drive Growth of Pharmaceutical Spending in the U.S. ( 1 ) BLUE CROSS BLUE SHIELD, THE HEALTH OF
More informationPharmaceutical Law & Industry Report
Pharmaceutical Law & Industry Report Reproduced with permission from Pharmaceutical Law & Industry Report, 16 PLIR 199, 02/09/2018. Copyright 2018 by The Bureau of National Affairs, Inc. (800-372-1033)
More informationWhy even have this talk? Disclosures. What will biosimilars mean for us? Annual Revenue Due to Adalimumab. Biosimilars 2017: What We Need to Know
Biosimilars 2017: What We Need to Know Why even have this talk? Miguel Regueiro, M.D. Professor of Medicine IBD Clinical Medical Director Senior Medical Lead, Specialty Medical Homes University of Pittsburgh
More informationInflation Near 10% Drug Price Growth Nearly Flat at 0.2%
Drug Trend Report 2017 Despite AWP Inflation Near 10% CVS Health Kept Drug Price Growth Nearly Flat at 0.2% and Adherence Improved Drug Trend Report 2017 In 2017, despite AWP inflation ~10% our strategies
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationThe Payor s Perspective: Regulating to incentivise value creation and repair a failed market
CLINICAL INNOVATION: Fair & Effective Incentives for New Uses of Established Drugs The Payor s Perspective: Regulating to incentivise value creation and repair a failed market Moderator: Nancy E. Taylor
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationBiosimilars. Their regulatory status and their use
Biosimilars Their regulatory status and their use Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific
More informationFinancial results for the fiscal year ending March 2016
Unlimited Drug Discovery from the Beginning Financial results for the fiscal year ending March 2016 20 th May, 2016 Stock Code: 4584 0 1 Representative Establishment March 2001 Masanari Kawaminami, President
More informationThe Future of the U.S. Biosimilars Market: Development, Education, and Utilization. October 18, 2016
The Future of the U.S. Biosimilars Market: Development, Education, and Utilization October 18, 2016 ABOUT THE DUKE MARGOLIS CENTER FOR HEALTH POLICY The Duke-Robert J. Margolis, MD, Center for Health Policy,
More informationMARCH Express Scripts 2015 Drug Trend Report Executive Summary
MARCH 2016 Express Scripts 2015 Drug Trend Report Executive Summary Together we brought down out-of-pocket costs for patients and slowed the increase in U.S. drug spend. G oing into 2015, healthcare payers
More informationBiosimilar vs. Generic, What s the Difference?
Biosimilar vs. Generic, What s the Difference? Kelly Peddy, PharmD, MPA, BCACP Clinical Pharmacy Specialist Ambulatory Care Memorial Hospital of South Bend A presentation for HealthTrust members December
More informationManaging Your Drug Spend. Discussion Topics 8/10/2016. Robert P. Navarro, PharmD Clinical Professor Department of Pharmaceutical Outcomes & Policy
Managing Your Drug Spend Robert P. Navarro, PharmD Clinical Professor Department of Pharmaceutical Outcomes & Policy 2 Discussion Topics Introduction and overview Market conditions, expense centers, and
More informationAn innovative solution to the rising cost of drug-benefit plans
An innovative solution to the rising cost of drug-benefit plans INTRODUCED BY Biologics Savings Partnership CANADIAN DRUG PLAN SPENDING ON SPECIALTY DRUGS, INCLUDING BIOLOGICS, CONTINUES TO INCREASE 1,2
More informationClinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View)
Athens, May 25, 2018 Clinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View) Vs18e28 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy &
More informationNHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars
NHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars Angela McFarlane Market Development Director, QuintilesIMS Angela.McFarlane@QuintilesIMS.com Copyright 2016 QuintilesIMS.
More informationBiosimilars Switching: What is Left to Learn?
Biosimilars Switching: What is Left to Learn? Jonathan Kay, MD Professor of Medicine Timothy S. and Elaine L. Peterson Chair in Rheumatology UMass Memorial Medical Center University of Massachusetts Medical
More informationEffect of Naming on Competition and Innovation. Mark McCamish, MD, PhD Global Head Biopharmaceutical Development Washington, DC 10 December 2013
Effect of Naming on Competition and Innovation Mark McCamish, MD, PhD Global Head Biopharmaceutical Development Washington, DC 10 December 2013 1 FTC Biosimilars Workshop on Naming Proposals and Impact
More informationSPECIALTY PHARMACY : ARE YOU MISSING OUT ON A VIABLE REVENUE STREAM. January 16, 2018
SPECIALTY PHARMACY : ARE YOU MISSING OUT ON A VIABLE REVENUE STREAM January 16, 2018 Agenda Defining Specialty Pharmacy and its revenue trends Rationale for the immense growth and how to leverage the cost
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Department of Origin: Pharmacy Department(s) Affected: Integrated Healthcare Services and Pharmacy 09/13/18 Pharmacy Criteria Document: Biologics for Psoriatic Arthritis: infliximab, Orencia, and Simponi
More informationThijs J Giezen, PharmD, MSc, PhD The Netherlands
Thijs J Giezen, PharmD, MSc, PhD The Netherlands Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem, The Netherlands Member of the Biosimilar Medicinal Product Working Party of European
More informationEmerging Biologics: Positioning of Thailand
2010/SOM3/LSIF/017 Emerging Biologics: Positioning of Thailand Submitted by: Thailand Center of Excellence for Life Sciences (TCELS) Life Sciences Innovation Forum Sendai, Japan 18-19 September 2010 Emerging
More informationCelltrion ( KQ)
Celltrion (068270 KQ) Buy (Initiate) Target Price (12M, W) 36,000 Share Price (09/03/12, W) 29,650 Expected Return (%) 21.4 EPS Growth (12F, %) 2.7 Market EPS Growth (12F, %) 12.7 P/E (12F, x) 29.9 Market
More informationEvolving U.S. Biosimilars Landscape
Evolving U.S. Biosimilars Landscape A Medical Affairs Perspective By Thao Sutter and Bryan Katz Syneos Health Consulting 2018 Syneos Health. All rights reserved. Introduction The U.S. biosimilar landscape
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationCoherus BioSciences. Jefferies 2016 Healthcare Conference. June 8, Copyright 2016 All Rights Reserved.
Coherus BioSciences Jefferies 2016 Healthcare Conference June 8, 2016 Copyright 2016 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein, the matters
More informationBiologics and Biosimilars: Background and Key Issues
Biologics and Biosimilars: Background and Key Issues (name redacted) Specialist in Biomedical Policy October 27, 2017 Congressional Research Service 7-... www.crs.gov R44620 Summary A biological product,
More informationWhat is a biosimilar and how does sound biosimilar use look like?
Vs14f17 LBP Opleidingsinstituut voor Care & Cure: Biosimilars in the Market; what does it mean for us? Rotterdam, June 18, 2014. What is a biosimilar and how does sound biosimilar use look like? Arnold
More informationREFERENCE CODE GDHC268CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC268CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in China The Rheumatoid Arthritis
More informationMANAGEDCAREBIOSIMILARS UPDATE: 2017 POLICY INITIATIVES & FORMULARY IMPACT
MANAGEDCAREBIOSIMILARS UPDATE: 2017 POLICY INITIATIVES & FORMULARY IMPACT Steven Lucio, PharmD, BCPS AVP, Clinical Solutions and Pharmacy Program Development Vizient Irving, Texas Steven G. Avey, MS, RPh,
More informationBiosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective)
Soul, September 14, 2017 Biosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective) Vs17i13 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy
More informationLAW: Primer on biosimilar agents
AND AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS 2 CPE CREDITS EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM Educational Objectives After participating
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (FINAL) Etanercept (Erelzi Sandoz Canada Inc.) Indications: Rheumatoid Arthritis, Ankylosing Spondylitis, Polyarticular Juvenile
More information2006 Focus on Specialty Pharmacy
TrendsRx Focus on Specialty Pharmacy Biotech and specialty pharmaceuticals offer groundbreaking medical advances in the treatment of complex illnesses. These products are high cost, but have made the most
More informationCoherus BioSciences. Jefferies 2016 London Healthcare Conference. November 16, Copyright 2016 All Rights Reserved.
Coherus BioSciences Jefferies 2016 London Healthcare Conference November 16, 2016 Copyright 2016 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein,
More informationPHARMACY TIMES BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT November 20, 2013
PHARMACY TIMES BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT November 20, 2013 We would like to inform you of the following changes to the 2013 IEHP that were approved by the Pharmacy and Therapeutics Subcommittee
More informationOvercoming Challenges in the Emerging Biosimilar Landscape
Overcoming Challenges in the Emerging Biosimilar Landscape Steven R. Feldman, M.D., Ph.D. Wake Forest University School of Medicine Winston Salem, North Carolina, USA Objectives Identify the safety and
More informationExpectation for the future and the role of the JP
JP 130 th Anniversary Symposium (15 September, 2016) Expectation for the future and the role of the JP From Academia s perspectives Toru KAWANISHI, PhD Director-General National Institute of Health Sciences
More informationPharmacy Benefit Management (PBM) Overview
Pharmacy Benefit Management (PBM) Overview Agenda Introductions to ARMSRx Team & Services Stephanie Cormier Christine Heutinck The PBM history and role in healthcare CIS key performance indicators (KPIs)
More informationPharmacy Benefit Management: Strategies and Approaches for Managing Prescription Drug Costs
Pharmacy Benefit Management: Strategies and Approaches for Managing Prescription Drug Costs Adrian Washington PharmD., MBA Vice President of Client Management UnitedHealthcare / OptumRx Agenda 1. Discuss
More informationLife Sciences. Key issues for senior life sciences executives
Life Sciences 2016 Key issues for senior life sciences executives Biosimilars in Canada: at a tipping point J Bradley White and Nathaniel Lipkus Osler, Hoskin & Harcourt LLP Helping you unlock the value
More informationBiosimilars. CancerCare. Booklet Series. and Their Role in Cancer Treatment.
Biosimilars and Their Role in Cancer Treatment CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series offers up-to-date, easy-to-read information on the latest treatments,
More informationAsia s Clout in Global Biosimilars
MIRAE ASSET LENS 4Q 2017 Mirae Asset Global Investments (Hong Kong) Asia Pacific Investment / Research Saniel Chandrawat, Senior Investment Analyst Sizing up the opportunity The global biosimilar market
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationGlobal Biosimilar Market Trends & Opportunities: 2015 Edition
Global Biosimilar Market Trends & Opportunities: 2015 Edition Global Biosimilar Market Trends & Opportunities: 2015 Edition BioPortfolio has been marketing business and market research reports from selected
More informationDelivering on the Potential of Biosimilar Medicines
March 2016 Delivering on the Potential of Biosimilar Medicines The Role of Functioning Competitive Markets Introduction As biologic medicines play a more significant role in patient care across a growing
More informationAvailability, Health-Care Costs, and Utilization Patterns of Biologics in Taiwan
VALUE IN HEALTH 15 (2012) S35 S42 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Availability, Health-Care Costs, and Utilization Patterns of Biologics in Taiwan
More information5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference
5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference September 18-20, 2017 Washington, DC Biosimilars: Price, Policy & Outlook Ron Lanton III, Esq. President
More informationOptimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances
Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health
More informationContinued Development of Approved Biological Drugs
Continued Development of Approved Biological Drugs A Quantitative Study of Additional Indications Approved Postlaunch in the United States White Paper December 2007 Maya Said Charles-André Brouwers Peter
More informationHealth. bulletin. Important: Formulary Drug Removals DECEMBER 2017
P.O. Box 16688 Phoenix, Arizona 85011 (888) 331-0222 www.svckairoshealthaz.org DECEMBER 2017 Health bulletin Some people look forward to the holidays all year, while others see the holiday season approaching
More informationUnderstanding Biosimilars and Projecting the Cost Savings to Employers Update
Understanding Biosimilars and Projecting the Cost Savings to Employers Update Prepared by: Milliman, Inc. Frank Kopenski Jr, ASA, MAAA Principal and Consulting Actuary Katie Holcomb, FSA, MAAA Actuary
More informationThe Future Role of Biosimilars: An Unknown Frontier in IBD Treatment
The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment Miguel Regueiro, MD, FACG Professor of Medicine Medical Director, IBD Center Senior Medical Lead, Specialty Homes University of Pittsburgh
More informationBiosimilars today or tomorrow?
Oxford Inflammatory Bowel Disease MasterClass Biosimilars today or tomorrow? Dr Vipul Jairath Bsc DPhil MRCP NIHR Clinical Lecturer Translational Gastroenterology Unit University of Oxford John Radcliffe
More informationMedImpact 2018 Meeting
MedImpact 2018 Meeting Doug Long Vice President, Industry Relations doug.long@iqvia.com March 2018 Copyright 2017 IQVIA. All rights reserved. Key happenings in 2017! Snapshot of key happenings in the industry
More informationBIOSIMILARS: CHALLENGES AND OPPORTUNITIES
BIOSIMILARS: CHALLENGES AND OPPORTUNITIES SATURDAY/4:30-5:30PM ACPE UAN: 0107-9999-17-255-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists: Upon completion of this
More informationBiosimilars, Utilization, and Post- Marketing Surveillance in the United States
Biosimilars, Utilization, and Post- Marketing Surveillance in the United States Michael D. Blum, MD, MPH Deputy Director, CDER Office of Pharmacovigilance and Epidemiology FDA Mark Cziraky, PharmD, CLS
More informationPAAB Workshop. Advertising Jurisdiction Lead & Key Trend Advertising of Biosimilars. November 15, 2017
PAAB Workshop Advertising Jurisdiction Lead & Key Trend Advertising of Biosimilars November 15, 2017 Alain Musende, PhD Manager, Therapeutic Effectiveness & Policy Bureau Health Canada Purpose: To discuss:
More informationSwitching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far
Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far Authors: *Anna La Noce, 1 Marcin Ernst 2 1. General Medicine, Syneos Health, Saronno,
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More information